{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:55:45Z","timestamp":1791633345251,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.therap.2024.11.008","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T16:50:22Z","timestamp":1733331022000},"page":"241-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Monitoring opioid analgesic misuse, abuse and dependence: What to the data from addictovigilance tell us about the situation in France?"],"prefix":"10.1016","volume":"80","author":[{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celian","family":"Bertin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constan\u00e7a","family":"Jalles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Soeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Roussin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2024.11.008_bib0290","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.therap.2016.05.001","article-title":"Twenty-five years of the French Addictovigilance Network (FAN)","volume":"71","author":"Micallef","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.11.008_bib0295","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/clpt.2010.154","article-title":"Prescription drug abuse: insight into the epidemic","volume":"88","author":"Hernandez","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2024.11.008_bib0300","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMsa1406143","article-title":"Trends in opioid analgesic abuse and mortality in the United States","volume":"372","author":"Dart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2024.11.008_bib0305","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/AJP.0000000000000426","article-title":"Trends in the nonmedical use of OxyContin, United States, 2006 to 2013","volume":"33","author":"Jones","year":"2017","journal-title":"Clin J Pain"},{"key":"10.1016\/j.therap.2024.11.008_bib0310","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000337028","article-title":"Misuse of medicines in the European Union: a systematic review of the literature","volume":"18","author":"Casati","year":"2012","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.therap.2024.11.008_bib0315","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/187447370801150611184218","article-title":"The misuse of prescription opioids: a threat for Europe?","volume":"8","author":"van Amsterdam","year":"2015","journal-title":"Curr Drug Abuse Rev"},{"key":"10.1016\/j.therap.2024.11.008_bib0320","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/ejp.1786","article-title":"Is Europe also facing an opioid crisis?\u00a0\u2013\u00a0A survey of European Pain Federation chapters","volume":"25","author":"H\u00e4user","year":"2021","journal-title":"Eur J Pain"},{"key":"10.1016\/j.therap.2024.11.008_bib0325","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/14659891.2023.2213325","article-title":"Misuse of psychoactive medicines and its consequences in the European Union\u00a0\u2013\u00a0a scoping review","volume":"29","author":"Carmona Ara\u00fajo","year":"2023","journal-title":"J Subst Use"},{"key":"10.1016\/j.therap.2024.11.008_bib0330","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3917\/psyt.191.0065","article-title":"Addiction m\u00e9dicamenteuse\u00a0: quelles donn\u00e9es pour \u00e9valuer et pr\u00e9venir\u00a0?","volume":"19","author":"Lapeyre-Mestre","year":"2013","journal-title":"Psychotropes"},{"key":"10.1016\/j.therap.2024.11.008_bib0335","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2515\/therapie\/2013021","article-title":"\u201cSerious\u201d adverse drug reactions with tramadol: a 2010\u20132011 pharmacovigilance survey in France","volume":"68","author":"Abadie","year":"2013","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.11.008_bib0340","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2515\/therapie\/2014221","article-title":"Evaluation of abuse and dependence in addiction monitoring systems: tramadol as an example","volume":"70","author":"Roussin","year":"2015","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.11.008_bib0345","series-title":"Neuropathology of drug addictions and substance misuse","article-title":"Weak opioid analgesics abuse and addiction: a comparison of the pharmacology and pharmacoepidemiology of codeine, dihydrocodeine, and tramadol","author":"Roussin","year":"2016"},{"key":"10.1016\/j.therap.2024.11.008_bib0350","first-page":"89","article-title":"Doctor shopping reveals geographical variations in opioid abuse","volume":"16","author":"Nordmann","year":"2013","journal-title":"Pain Physician"},{"key":"10.1016\/j.therap.2024.11.008_bib0355","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.drugalcdep.2018.01.036","article-title":"Doctor shopping of opioid analgesics relative to benzodiazepines: a pharmacoepidemiological study among 11.7 million inhabitants in the French countries","volume":"187","author":"Ponte","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2024.11.008_bib0360","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.therap.2019.11.002","article-title":"French trends in the misuse of Fentanyl: from 2010 to 2015","volume":"75","author":"Tournebize","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.11.008_bib0365","unstructured":"Agence fran\u00e7aise de s\u00e9curit\u00e9 des m\u00e9dicaments et des produits de sant\u00e9\u00a0\u2013\u00a0ANSM. Use and abuse of opioid analgesics\u00a0\u2013\u00a0Situation Report. February 2019. https:\/\/ansm.sante.fr\/uploads\/2020\/10\/19\/20201019-rapport-antalgiques-opioides-fev-2019-gb.pdf [Accessed 15 November 2024 (52 pp.)]."},{"key":"10.1016\/j.therap.2024.11.008_bib0370","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/bcp.13564","article-title":"Trends in analgesic consumption in France over the last 10 years and comparison of patterns across Europe","volume":"84","author":"Hider-Mlynarz","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.11.008_bib0375","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bcp.14415","article-title":"Ten-year trend of opioid and nonopioid analgesic use in the French adult population","volume":"87","author":"Daveluy","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.11.008_bib0380","doi-asserted-by":"crossref","first-page":"e2331398","DOI":"10.1001\/jamanetworkopen.2023.31398","article-title":"Trends in fatal poisoning among drug users in France from 2011 to 2021: an analysis of the DRAMES register","volume":"6","author":"Revol","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.therap.2024.11.008_bib0385","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.puhe.2024.08.019","article-title":"Trends in fatal poisoning among medical users of analgesics in France from 2013 to 2022: an analysis of the DTA register","volume":"236","author":"Revol","year":"2024","journal-title":"Public Health"},{"key":"10.1016\/j.therap.2024.11.008_bib0390","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1111\/bcp.15323","article-title":"Increase of high-risk tramadol use and harmful consequences in France from 2013 to 2018: evidence from the triangulation of addictovigilance data","volume":"88","author":"Roussin","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.11.008_bib0395","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.therap.2020.06.006","article-title":"Addictovigilance contribution during COVID-19 epidemic and lockdown in France","volume":"75","author":"Lapeyre-Mestre","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.11.008_bib0400","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.therap.2023.10.017","article-title":"Psychoactive substance intoxication leading to general hospital admission in young and middle-aged people during and after the first lockdown","volume":"79","author":"Perino","year":"2024","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.11.008_bib0405","unstructured":"Institut national de la sant\u00e9 et de la recherche m\u00e9dicale\u00a0\u2013\u00a0Inserm. M\u00e9dicaments psychotropes\u00a0: consommations et pharmacod\u00e9pendances. Paris. 2012. https:\/\/www.ipubli.inserm.fr\/handle\/10608\/2071 [Accessed 15 November 2024]."},{"key":"10.1016\/j.therap.2024.11.008_bib0410","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2515\/therapie\/2011037","article-title":"Evolution of opioids reimbursement since 2004 from the National Database of the General Health Insurance System","volume":"66","author":"Pauly","year":"2011","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.11.008_bib0415","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drugalcdep.2012.03.009","article-title":"Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France","volume":"126","author":"Pauly","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2024.11.008_bib0420","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00228-014-1783-x","article-title":"Detection of signals of abuse and dependence applying disproportionality analysis","volume":"71","author":"Pauly","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.11.008_bib0425","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000346179","article-title":"Slow-release oral morphine sulfate abuse: results of the postmarketing surveillance systems for psychoactive prescription drug abuse in France","volume":"19","author":"Peyriere","year":"2013","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.therap.2024.11.008_bib0430","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/j.pain.0000000000002093","article-title":"Evolution of doctor shopping for oxycodone in the 67 million inhabitants in France as a proxy for potential misuse or abuse","volume":"162","author":"Soeiro","year":"2021","journal-title":"Pain"},{"key":"10.1016\/j.therap.2024.11.008_bib0435","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2515\/therapie\/2015009","article-title":"Signal identification in addictovigilance: the functioning of the French system","volume":"70","author":"Jouanjus","year":"2015","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.11.008_bib0440","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.therap.2019.09.005","article-title":"Safety signal detection by the French Addictovigilance Network: innovative methods of investigation, examples and usefulness for public health","volume":"74","author":"Micallef","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.11.008_bib0445","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S2468-2667(19)30128-8","article-title":"Trends in use and misuse of opioids in the Netherlands: a retrospective, multi-source database study","volume":"4","author":"Kalkman","year":"2019","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.therap.2024.11.008_bib0450","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/ejp.1291","article-title":"Prescription opioid analgesic use in France: trends and impact on morbidity-mortality","volume":"23","author":"Chenaf","year":"2019","journal-title":"Eur J Pain"},{"key":"10.1016\/j.therap.2024.11.008_bib0455","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1192\/j.eurpsy.2021.2219","article-title":"Is Europe facing an opioid crisis like the United States? An analysis of opioid use and related adverse effects in 19 European countries between 2010 and 2018","volume":"64","author":"Pierce","year":"2021","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.therap.2024.11.008_bib0460","doi-asserted-by":"crossref","first-page":"100437","DOI":"10.1016\/j.lanepe.2022.100437","article-title":"Opioid sales and opioid-related poisonings in Switzerland: a descriptive population-based time-series analysis","volume":"20","author":"Hooijman","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.therap.2024.11.008_bib0465","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1002\/ejp.2011","article-title":"Trends in opioid utilization in Hungary, 2006\u20132020: a nationwide retrospective study with multiple metrics","volume":"26","author":"Engi","year":"2022","journal-title":"Eur J Pain"},{"key":"10.1016\/j.therap.2024.11.008_bib0470","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/01410768221077360","article-title":"Trends and characteristics of hospitalisations from the harmful use of opioids in England between 2008 and 2018: population-based retrospective cohort study","volume":"115","author":"Friebel","year":"2022","journal-title":"J R Soc Med"},{"key":"10.1016\/j.therap.2024.11.008_bib0475","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/add.16081","article-title":"The opioid epidemic: a worldwide exploratory study using the WHO pharmacovigilance database","volume":"118","author":"Robert","year":"2023","journal-title":"Addiction"},{"key":"10.1016\/j.therap.2024.11.008_bib0480","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/bcp.14791","article-title":"Measuring prescription opioid misuse and its consequences","volume":"87","author":"Dart","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.11.008_bib0485","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.therap.2024.10.055","article-title":"ASOS, a national monitoring study to assess narcotic prescriptions and indications in France since 2001","volume":"80","author":"Perri-Pland\u00e9","year":"2025","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.11.008_bib0490","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/fcp.12368","article-title":"Tamper-resistant prescription forms for narcotics in France: should we generalize them?","volume":"32","author":"Daveluy","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.11.008_bib0495","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40264-021-01124-5","article-title":"A 13-year national monitoring study to assess narcotic prescriptions and indications (2007\u20132019)","volume":"45","author":"Perri-Plande","year":"2022","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2024.11.008_bib0500","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.therap.2024.10.059","article-title":"DRAMES and DTA databases: complementary tools to monitor drug-related deaths in France","volume":"80","author":"Revol","year":"2025","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.11.008_bib0505","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.therap.2024.10.054","article-title":"Monitoring misuse and abuse of psychoactive substances in France: insights from substance abuse treatment facilities through the OPPIDUM program","volume":"80","author":"Lacroix","year":"2025","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.11.008_bib0510","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.therap.2018.09.007","article-title":"Consommation d\u2019analg\u00e9siques chez les sujets pr\u00e9sentant un trouble d\u2019usage de substances","volume":"73","author":"Pont\u00e9","year":"2018","journal-title":"Therapies"},{"key":"10.1016\/j.therap.2024.11.008_bib0515","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2515\/therapie\/2012037","article-title":"General practitioners\u2019 contribution to dependence assessment: the OPEMA programme","volume":"67","author":"Moracchini","year":"2012","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.11.008_bib0520","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1111\/bcp.14082","article-title":"Risk assessment of using off-label morphine sulfate in a population-based retrospective cohort of opioid-dependent patients","volume":"86","author":"Bertin","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.11.008_bib0525","doi-asserted-by":"crossref","first-page":"893590","DOI":"10.3389\/fpsyt.2022.893590","article-title":"Oral Morphine as an alternative substitution treatment for opioid use disorder, a rare but non-risk-free use","volume":"13","author":"Bertin","year":"2022","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.therap.2024.11.008_bib0530","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12954-023-00866-y","article-title":"People who inject oral morphine favor experimentation with injectable opioid substitution","volume":"20","author":"Bertin","year":"2023","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.therap.2024.11.008_bib0535","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.therap.2024.10.053","article-title":"From the first pilot initiatives in the early 1990s to the national OSIAP survey in the 2020s: more than 30 years of insight in medication diversion phenomenon in France","volume":"80","author":"Lapeyre-Mestre","year":"2025","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.11.008_bib0540","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00228-001-0412-7","article-title":"Forged medical prescriptions in a community pharmacy network in Midi-Pyr\u00e9n\u00e9es area: assessment of a falsification ratio","volume":"57","author":"Llau","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.11.008_bib0545","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1111\/bcp.15052","article-title":"Medical prescription forms of opioid cough suppressants falsified by the patients before and after they switched from over-the-counter to prescription-only in France","volume":"88","author":"Jouanjus","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.11.008_bib0550","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.therap.2024.10.058","article-title":"Inputs of pharmacoepidemiology in addictovigilance: how do they fit together?","volume":"80","author":"Soeiro","year":"2025","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.11.008_bib0555","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/add.16261","article-title":"Systematic assessment of non-medical use of prescription drugs using doctor-shopping indicators: a nation-wide, repeated cross-sectional study","volume":"118","author":"Soeiro","year":"2023","journal-title":"Addiction"},{"key":"10.1016\/j.therap.2024.11.008_bib0560","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s10571-020-01013-y","article-title":"Oxycodone in the opioid epidemic: high \u2018liking\u2019, \u2018wanting\u2019, and abuse liability","volume":"41","author":"Kibaly","year":"2021","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.therap.2024.11.008_bib0565","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1124\/pharmrev.121.000506","article-title":"Oxycodone: a current perspective on its pharmacology, abuse, and pharmacotherapeutic developments","volume":"75","author":"Barrett","year":"2023","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.therap.2024.11.008_bib0570","doi-asserted-by":"crossref","first-page":"1229439","DOI":"10.3389\/fpsyt.2023.1229439","article-title":"Oxycodone, an opioid like the others?","volume":"14","author":"Marie","year":"2023","journal-title":"Front Psychiatry"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724002105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724002105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:34:52Z","timestamp":1744202092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595724002105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0040595724002105"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2024.11.008","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monitoring opioid analgesic misuse, abuse and dependence: What to the data from addictovigilance tell us about the situation in France?","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2024.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}